AKT Inhibition in Prostate Cancer — Proceedings from a Session Held Adjunct to the 2026 ASCO Genitourinary Cancers Symposium
Oncology Today with Dr Neil Love
00:00
Where AKT Inhibitors Fit Clinically
Daniel George argues for early use in PTEN-deficient mHSPC to block aggressive biology before further alterations.
Play episode from 51:43
Transcript
